BIOEMTECH is a high-tech company offering innovative services and products in pharmaceutical and medical research. It has developed an in-vivo imaging platform for experimental animals aimed at understanding the molecular mechanisms of living organisms. The vision of BIOEMTECH is to change the way pharmaceutical research is conducted, to accelerate it, and to provide innovative, daily tools in the field of preclinical research for the evaluation of new radiopharmaceuticals and the study of nanoparticles.
BIOEMTECH has two laboratory facilities, one of which is located at the NCSR “Demokritos” and includes infrastructure for in vitro studies, radiochemistry, toxicology, and in vivo imaging with SPECT, PET, CT, and Optical systems.
The company’s activities extend to the field of digital health, providing smart solutions, tools, and services for optimizing clinical and preclinical protocols. Specifically, the company’s software department has specialized knowledge in the design of Monte Carlo simulations and the development of Artificial Intelligence (Machine Learning) algorithms. The company has established itself in the digital health field through participation and coordination of European projects, the development of innovative Decision Support Systems (DSS), and its recognition in the EU Innovation Radar.
The BIOEMTECH team consists of 38 young researchers specialized in various fields such as biotechnology, bioinformatics, medical physics, biology, engineering, and radiochemistry. The company was founded in 2013 and to date has participated in 9 H2020, 4 ERANET, 1 FF4EuroHPC, 1 COST, and 3 NSRF funded research programs, and is an official member of the international networks ETPN, OpenGATE, EARA, and the national clusters HBio and HDHC.